Posts

Posted on

Reimagining Downtowns Can Unlock $120+ Billion in Untapped Value

Reimagining Downtowns Can Unlock $120+ Billion in Untapped Value

Cushman & Wakefield releases Reimagining Urban Real Estate Portfolios report examining the asset mix in urban centers

NEW YORK–(BUSINESS WIRE)–
A new report by Cushman & Wakefield (NYSE: CWK), Reimagining Urban Real Estate Portfolios, finds that there is significant value to be unlocked in Downtowns if cities, investors and other stakeholders act swiftly to rebalance their real estate portfolios. The current mix of real estate uses in most U.S. Downtowns is misaligned with optimal real estate portfolio theory. This mismatch has left many urban cores exposed to persistent vacancies, reduced foot traffic, declining property values, and growing fiscal pressure. The report outlines how repurposing real estate uses in Downtowns—and possibly, other walkable urban places—could revitalize cities and unlock as much as $340 billion in value.

“Downtowns are currently over-indexed on office space, averaging 70% of total real estate use compared to the ideal ~40%,” said Rebecca Rockey, Deputy Chief Economist at Cushman & Wakefield. “That imbalance has made them less resilient in the wake of the pandemic, remote work and economic disruption, and now, ripe for targeted reinvention.”

Key findings from the report include:

  • Downtowns are disproportionately reliant on office real estate, which has contributed to steadily rising vacancy rates now exceeding 26% and sharp valuation declines in many cities.

  • Strategic conversions of lower-quality office buildings into residential or entertainment uses, referred to as “Live” or “Play” space, could unlock between $105 billion and $208 billion in value across 15 major U.S. Downtowns.

  • Asset quality is critical to successful conversion outcomes. The greatest value is achieved when lower-value office buildings are repositioned into higher-value residential or entertainment assets. The report stresses the need for targeted, quality-focused investment.

  • Non-Downtown Walkable Urban Places (WalkUPs) are generally closer to the ideal real estate mix. Broad conversion efforts in these areas could reduce value, but carefully selected projects still present compelling opportunities.

  • There is urgency to act. Declining property tax revenues, reduced foot traffic, and increasing retail vacancies are creating uneven risks to urban economic health. Without focused policy action and investment, cities could face long-term fiscal strain and growing challenges to revitalize their urban cores.

  • No two cities have the same real estate or property tax fingerprint. City governments need to engage with all stakeholders to understand what incentives and incentive structures could have the biggest impact.

The report also highlights how unique each U.S. city is—the challenges and opportunities vary. Miami, as an example, has a Downtown with a more balanced real estate mix that more closely mirrors the optimal portfolio. This is one reason it has been more resilient and has actually seen Downtown foot traffic grow since 2019. This points to the fact that cities with a healthier balance of residential, office and entertainment uses can support economic vitality and remain more resilient even during disruptive shifts. Other cities are taking notice, but swift action is needed.

“This is a call to action for real estate owners, civic leaders, and investors,” said David Smith, Head of Americas Insights. “The data shows that smart, targeted redevelopment in our Downtowns can create real financial returns and strengthen the overall vitality of cities.”

The report comes at a time when many municipalities are facing severe budget shortfalls. Cities like New York, San Francisco, Boston, and Chicago project multi-billion-dollar deficits driven largely or in part by falling office values and tax base erosion. Reimagining Urban Real Estate Portfolios offers a roadmap for action, identifying where conversions will be most effective and how they can help rebuild vibrant, resilient urban cores.

The full report by Cushman & Wakefield can be found here.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of $9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com

Michael Boonshoft

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Finance Construction & Property Asset Management Urban Planning REIT

MEDIA:

Logo
Logo
Posted on

Pony.ai Attracts Premium Capital as Funds Chase the Next Tech Transformation

PR Newswire


GUANGZHOU, China
, Aug. 18, 2025 /PRNewswire/ — Leading investment management firms are backing Pony.ai.

Recent corporate filings reveal ARK Invest, Cathie Wood’s firm, invested roughly US$12.9 million in the Chinese autonomous driving company in August. This marks ARK’s first investment in a Chinese firm solely focused on Level 4 (L4) autonomous driving technology development and commercialization.

ARK wasn’t alone in backing Pony.ai. Exchange and corporate filings reveal the robotaxi operator attracted at least 14 major global institutional investors in Q2, including prominent names like Baillie Gifford and Nikko Asset Management – firms renowned for successful investments in Tesla, Tencent, Alibaba, and Meituan. This broad backing stands in sharp contrast to many U.S. investors shifting away from Chinese assets amid geopolitical tensions and tariffs clouding the growth outlook.

ARK’s strategy is clear: invest in emerging high-tech companies Wood believes can transform industries. As detailed in ARK’s “Big Ideas 2025” report, the firm projected the ride-hailing market could surge to a US$10 trillion value by 2030, with global robotaxi fleets potentially reaching around 50 million vehicles. As Wood has emphasized, a robotaxi company’s success hinges significantly on its cost optimization. Pony.ai’s recent earnings and outlook provided compelling reasons for investor confidence.

In Q2, the company reported a striking 158% year-on-year increase in robotaxi revenues. This growth was supported by the ramped-up production of its seventh-generation robotaxi models. By expanding its fleet and securing more regulatory permits in densely populated urban centers, Pony.ai is meeting rising user demand.

More importantly, Pony.ai outlined a clear path to profitability – offering the rare certainty investors seek.

Founder and CEO James Peng highlighted key factors in a recent CNBC interview: “Unit economics are paramount. The Gen-7 vehicle boasts a 70% lower cost than its predecessor. We’ve also significantly reduced operational costs: our remote assistant-to-vehicle ratio has been significantly improved and it is expected to hit 1:30 by the end of the year, insurance costs fell 18%, and ground support and charging operations are more efficient.”

“Based on these metrics,” Peng added, “we are confident in Gen-7’s unit-level profitability. Further scaling the fleet will then drive corporate-level profitability.” Pony.ai targets a fleet of 1,000 robotaxis by year-end – a threshold the company believes will achieve positive unit economics. Progress is rapid: just two months after unveiling Gen-7 at the late-April Shanghai Auto Show, around 200 new vehicles have rolled off production lines, bringing the total fleet to roughly 500 units.

Beyond production, Pony.ai is accelerating user acquisition. Regulators recently granted the company a commercial permit to operate fare-charging services in parts of Shanghai’s Pudong areas, the financial heart of the eastern Chinese city. This makes Pony.ai the only company with fully-driverless commercial permits across all four Chinese tier-1 megacities (Beijing, Shanghai, Guangzhou, Shenzhen).

Service hours have also expanded to 24/7 in Guangzhou and Shenzhen. Furthermore, a recent partnership will integrate Pony.ai’s robotaxi service into Tencent’s ubiquitous WeChat platform, unlocking access to its massive user base exceeding one billion.

Bolstered by a clearer commercial outlook and solid safety and tech validation, Pony.ai is winning favor not just with funds, but also recognition from analysts. Following the Q2 earnings release, major institutions including Goldman Sachs, Huatai, UBS, and Daiwa all rated the stock “buy”. Goldman set a price target of US$24.5, indicating 54.5% upside compared to Pony.ai’s closing price of US$15.86 on August 15.

UBS analysts, in an Aug. 5 research note, stated: “By the late 2030s, we expect the robotaxi market value to reach US$183 billion in China and US$394 billion in international markets excluding the U.S., assuming gradual operational expansion and improving regulatory clarity.” Pony.ai is best positioned for robotaxi commercialization, the UBS analysts added.

Cision View original content:https://www.prnewswire.com/news-releases/ponyai-attracts-premium-capital-as-funds-chase-the-next-tech-transformation-302532297.html

SOURCE Pony.ai

Posted on

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

PR Newswire


SAN DIEGO
, Aug. 18, 2025 /PRNewswire/ — The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Alto Neuroscience, Inc. (NYSE: ANRO).

Investors who purchased in excess of $100,000 in shares of Alto Neuroscience, Inc. (NYSE: ANRO) between February 2, 2024 and October 22, 2024, have certain options and there are short and strict deadlines running. Deadline: September19, 2025. NYSE: ANRO investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

On July 21, 2025, a NYSE: ANRO investor filed a lawsuit over alleged securities laws violations by Alto Neuroscience, Inc. The plaintiff alleges that the Offering Documents that were filed in connection with the Company’s IPO conducted on or about February 2, 2024 and that certain statements made by the defendants between February 2, 2024 and October 22, 2024 were false and/or misleading statements and/or failed to disclose that ALTO-100 was less effective in treating MDD than Defendants had led investors to believe, that accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated, that as a result, Alto’s business and/or financial prospects were overstated, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased Alto Neuroscience, Inc. (NYSE: ANRO) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
[email protected] 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-deadline-investors-who-purchased-over-100-000-worth-of-shares-of-alto-neuroscience-inc-nyse-anro-between-feb-and-oct-2024-should-contact-the-shareholders-foundation-302531872.html

SOURCE Shareholders Foundation, Inc.

Posted on

Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare

PR Newswire

DTSS’ Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 Billion Globally by 2030


BEIJING
, Aug. 18, 2025 /PRNewswire/ — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), a Nevada-based technology enterprise specializing in advanced acoustic high-tech products and AI multimodal digital solutions, today announced a milestone breakthrough in its acoustic technology. The Company has successfully achieved an exciting leap forward in its acoustic core technologies with the integration of  sound wave coupling with AI; the first application for this innovative technology will be precision health management and clinical intervention.

Due to the rapidly growing demand for non-pharmaceutical precision health solutions and increasing policy support for healthcare, the Company is well-positioned to adress a market opportunity projected by research and consulting firm Grand View Research at approximately over $100 billion in China and nearly $90 billion globally by 2030.

Commercialization Engine Fully Activated

Leveraging its proprietary sound wave coupling technologies, Datasea has realized precise regulation of the nervous system—including intracranial, peripheral, and cardiac areas—as well as targeted foot acupoint stimulation. This has enabled the creation of a closed-loop ecosystem of detection–analysis–diagnosis–real-time intervention in core medical and health scenarios, with expected high clinical value.

By advancing the convergence of “Acoustics + Neurology,” Datasea has positioned ultrasound neuromodulation as its core product strategy. The Company has already developed innovative hardware products and solutions with medical-grade precision, achieved staged results, and commenced the initial phase of commercialization. These efforts not only open immediate revenue channels but also lay the foundation for deep engagement in the trillion-dollar healthcare ecosystem.

Ms. Zhixin Liu, Chief Executive Officer of Datasea, stated:
“This breakthrough in applying acoustic technology to healthcare marks a new stage in our commercialization journey. Through continuous innovation and deep integration with industry applications, we have developed acoustic products and solutions that deliver both clinical value and market potential, and we are fully prepared for commercialization.In order to rapidly advance this breakthrough technology, we are accelerating technology transfer, product deployment, and solution rollout through strategic collaborations. We expect these initiatives to drive sustained growth momentum. Further information and regarding business drivers and future plans will be communicated in the near future,, and we invite the capital markets to stay tuned！“

Expanding Access to a Billion-Dollar Market

This commercialization initiative is underpinned by Datasea’s strong acoustic technologies, which directly address critical pain points in healthcare industry upgrades. According to industry data provided by global market research firm International Data Corporation (IDC), relevant acoustic technology subfields are experiencing exponential growth, particularly in precision health management, where innovation is set to drive disruptive transformation.

As a continuous leader in acoustic technology, Datasea will use this breakthrough as a springboard to further advance technological iterations and accelerate the integration of clinical applications. The Company is committed to enabling intelligent upgrades in healthcare, contributing to global wellness, enhancing consumer experiences, and delivering sustainable value to its shareholders.

About Datasea Inc.

Datasea Inc. (“Datasea”) is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email:  investorrelations@shuhaixinxi.com
                        [email protected] 

Precept Investor Relations LLC

David Rudnick

+1 646-694-8538
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/datasea-achieves-breakthrough-in-acoustic-technology-accelerating-billion-dollar-commercialization-in-healthcare-302532075.html

SOURCE Datasea Inc.

Posted on

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

PR Newswire


SALT LAKE CITY
, Aug. 18, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th Annual Next Generation Dx Summit, held virtually and in-person at the Capital Hilton in Washington, D.C. on August 18-20, 2025.

Cambridge Healthtech Institute’s Next Generation Dx Summit is described as the nexus for international thought leaders to network and discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are improving the standard of care in the diagnostics industry.

Attendees are invited to visit the Company at Booth #12 to learn more about the Co-Dx Logix Smart® suite of clinical laboratory solutions, as well as the upcoming Co-Dx PCR diagnostics platform* and the pipeline of upper respiratory, tuberculosis and HPV tests, all of which the Company is anticipating entering into clinical evaluations during 2025.

To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.

Company travel and conference attendance is made possible due in part to a grant from World Trade Center Utah, a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships.


*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-17th-next-generation-dx-summit-in-washington-dc-302531996.html

SOURCE Co-Diagnostics

Posted on

Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform

PR Newswire

Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings


DUBLIN
, Aug. 18, 2025 /PRNewswire/ — Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity.

The investment follows the launch earlier this year of Aon’s subsidized GLP-1 weight management benefit program for its U.S. workforce – developed by eMed – which has delivered strong adherence, high retention and sustainable results for the firm’s colleagues. In the sixth months since Aon’s program launched, more than 1,200 people have registered and the firm has seen an average of 22.4 pounds lost with a retention rate of 95 percent.

With this investment, eMed will continue to increase distribution of its digital-first healthcare platform — which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support—to reach more employers and patients.

“As the leader of Aon’s People Organization, I know how important it’s been to include GLP-1 coverage as part of our own U.S. Total Rewards strategy,” said Lisa Stevens, Chief Administrative Officer for Aon. “When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses.”

Stevens added: “This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people. By aligning innovation with behavior change and accountability, together we can deliver sustainable results at scale.”

The collaboration marks a major milestone in eMed’s mission to deliver effective and sustainable care through an integrated, data-driven experience, while expanding its provider network, behavioral health tools and market reach.

“Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants,” said Linda Yaccarino, CEO of eMed Population Health, Inc. “Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence – helping employers reduce long-term health costs while improving quality of life for their people.”

Aon continues to build a complimentary suite of GLP-1 solutions, industry-leading experience and advisory capabilities for clients. In April, Aon unveiled findings from its multi-year analysis of U.S. commercial health claims data, which evidenced the transformative potential of GLP-1 medications in managing obesity and improving health outcomes. 

“The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions,” said Farheen Dam, Head of Health for North America at Aon. “We know that GLP-1s are not a one size fits all strategy. This is why data, modelling and strategic guidance from our clinical, actuarial and pharmacy teams help employers build GLP-1s strategies that fit their population and objectives.”

About eMed
eMed® is the world’s first end-to-end GLP-1 care platform built on Empathetic AI™. From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com. 

About Aon


Aon plc
 (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.

Media Contacts

eMed

Matt Gorman


[email protected]

Aon


[email protected]


Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114
International: +1 312 381 3024 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aon-announces-strategic-investment-in-emed-to-scale-glp-1-population-health-platform-302532181.html

SOURCE Aon plc

Posted on

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

PR Newswire

Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors


AUSTIN, Texas
, Aug. 18, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the Company’s lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Similarly, the European Patent Office has issued a Notice of Allowance to Genprex for a patent covering the use of REQORSA in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest.

“We are very proud to continue building a fortress of intellectual property protection around our oncology program for REQORSA, and these newly granted patents strengthen and expand our intellectual property estate for REQORSA in combination with immune checkpoint inhibitors applicable to our Acclaim-3 clinical trial,” said Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex.

Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel. Should these applications grant, they would be applicable to Genprex’s Acclaim-3 clinical trial.

Genprex has been granted patents for the use of REQORSA in combination with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea and Singapore.

PD-L1 and PD-1 antibodies are a type of targeted immunotherapy and a part of a group of checkpoint inhibitor anti-cancer drugs that block the activity of PD-L1 and PD-1 immune checkpoint proteins present on the surface of cells.

The Acclaim-3 study is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech’s Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration (FDA) Fast Track Designation for this patient population, and Acclaim-3 has received FDA Orphan Drug Designation.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2024.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex’s clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status, including Genprex’s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex’s intellectual property and licenses, including the potential for future grants of patent applications globally; and Genprex’s current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations

[email protected]

GNPX Media Contact

Kalyn Dabbs

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa-gene-therapy-with-pd-l1-and-pd-1-antibodies-to-treat-cancers-302531812.html

SOURCE Genprex, Inc.

Posted on

Gabelli Funds to Host 31st Annual Aerospace & Defense Symposium at The Harvard Club, New York City Thursday, September 4, 2025

GREENWICH, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) — Gabelli Funds, LLC, is hosting our annual Aerospace & Defense Symposium at The Harvard Club in New York City on September 4th. The conference will draw top executives from more than ten companies, with a focus on the themes of strong demand outlook, high barriers to entry, large aftermarket opportunity, growth in excess of GDP, defense spending, and M&A potential for the Aerospace and Defense industry. Attendees will also have the opportunity to meet with management in a one-on-one setting. Prospective attendees can learn more about the symposium on our website.

Featured Companies

AIRO Group Holdings, Inc. (NASDAQ: AIRO)   Elbit Systems Ltd. (NASDAQ: ESLT)
Albany International Corp. (NYSE: AIN)   Graham Corporation (NYSE: GHM)
Apex Aerospace (Private)   HEICO Corporation (NYSE: HEI)
AstraNav, Inc. (Private)   Moog Inc. (NYSE: MOG-A)
Astronics Corporation (NASDAQ: ATRO)   New Horizon Aircraft Ltd. (NASDAQ: HOVR)
Avio S.p.A. (Milan: AVIO)   Redwire Corporation (NYSE: RDW)
Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER)   Rheinmetall AG (XETRA: RHM)
Crane Company (NYSE: CR)   StandardAero, Inc. (NYSE: SARO)
Curtiss-Wright Corporation (NYSE: CW)   TAT Technologies Ltd. (NASDAQ: TATT)
DroneShield Limited (ASX: DRO)   Textron Inc. (NYSE: TXT)
Ducommun Incorporated (NYSE: DCO)    
     

The Harvard Club
, New
York City
Thursday, September 4, 2025 starting at 7:45 am

Registratio
n
link
:

CLICK HERE

Contact

General Inquiries

Isabella DeLuca

Client Relations
P: 914-921-5101
E :[email protected]

Sadie Keating

Marketing Associate
P: 914-921-5107
E :[email protected]

Research Team

Tony Bancroft

Portfolio Manager
P: 914-921-5083
E:[email protected]

Michael Burgio

Research Analyst
P: 914-921-7797
E:[email protected]

Daniel Gleim

Research Analyst
P: 914-921-7797
E:[email protected]

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc.

Contact:
Tony Bancroft, Portfolio Manager
(914) 921-5083



Posted on

Wingstop Reveals Next Drop: BOGO Chicken Tenders

PR Newswire

Double the tenders, double the flavor


DALLAS
, Aug. 18, 2025 /PRNewswire/ — Wingstop (NASDAQ: WING) is doubling down on flavor with the next Wingstop Drop – and this time, it is all about tenders. Starting today, August 18, through Sunday, August 24, fans can score Wingstop’s newest menu innovation (and more of it) with Buy-One-Get-One free 4-piece tenders*.

That’s 8 tenders – hand sauced-and-tossed in any 12 bold, distinctive flavors to choose from.  

“Tenders are having a moment. But Wingstop tenders are the best there are,” said Wingstop’s Chief Revenue Officer, Mark Christenson. “The response has been incredible, and we’re giving fans more of the tenders they’re craving with BOGO tenders all week long as their fantasy drafts close and preseason matchups intensify.”

Fans can claim their BOGO free 4-piece tenders with promo code BOGOTENDERS when they add an a la carte 4-piece tender to their order at Wingstop.com or in the Wingstop app – now, for a limited time.

For the latest on Wingstop Drops, fans can follow @Wingstop on TikTok, Instagram, X and Facebook.

*See Wingstop.com/Offers for full details.

About Wingstop

Founded in 1994 and headquartered in Dallas, TX, Wingstop Inc. (NASDAQ: WING) operates and franchises more than 2,800 restaurants worldwide – with 98% of the total restaurant count owned by brand partners. Dedicated to Serving the World Flavor, the Flavor Experts offer cooked-to-order and hand sauced-and-tossed classic and boneless wings, tenders and chicken sandwiches, in fans’ choice of 12 bold, distinctive flavors, with signature sides and iconic housemade ranch and bleu cheese dips. With approximately $5 billion in system-wide sales in fiscal 2024, 21 consecutive years of same-store sales growth and a vision to become a Top 10 Global Restaurant Brand, Wingstop was recently named the Official Chicken Partner of the NBA. Learn more at wingstop.com or follow @Wingstop on TikTok, Instagram, X and Facebook.

Media Contact

Maddie Lupori

[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wingstop-reveals-next-drop-bogo-chicken-tenders-302532241.html

SOURCE Wingstop Restaurants Inc.

Posted on

Performance Shipping Inc. Secures Time Charter Contract for M/T P. Aliki at US$30,000 Per Day

ATHENS, Greece, Aug. 18, 2025 (GLOBE NEWSWIRE) — Performance Shipping Inc. (NASDAQ: PSHG) (“we” or the “Company”), a global shipping company specializing in the ownership of tanker vessels, today announced that it has entered into a time charter contract with Pakistan National Shipping Corporation (“PNSC” or the “Charterer”) for its M/T P. Aliki, a 105,304 DWT LR2 Aframax tanker, built in 2010.

Under the agreement, the vessel will be chartered for a period of 12 months, plus or minus 15 days at the Charterer’s option, at a daily gross charter rate of US$30,000. The P. Aliki completed a six-month charter with Seariver Maritime LLC, a subsidiary of ExxonMobil Corporation, and is currently undergoing its third special survey and drydock. She will be delivered to the Charterer upon completion of the drydock, expected to be around mid-September 2025.

This charter increases the Company’s fleetwide secured revenue backlog by approximately US$10.5 million for the minimum duration of the charter, bringing the total to about US$250.5 million, based on the minimum duration of each charter and as of the end of the last financial reporting period.

Commenting on this charter, Andreas Michalopoulos, the Company’s Chief Executive Officer, stated:

“We are pleased to commence this new collaboration with Pakistan National Shipping Corporation, which highlights the diversity and global reach of our chartering relationships. The Company expects this time charter to generate earnings significantly above the vessel’s free cash flow breakeven level and contribute meaningfully to our earnings over the contracted period. This aligns with our strategy of securing attractive employment for our vessels in a dynamic market environment to maintain revenue visibility. We look forward to building on this relationship while continuing to deliver value to our shareholders.”

About the Company

Performance Shipping Inc. is a global provider of shipping transportation services through its ownership of tanker vessels. The Company employs its fleet on spot voyages, through pool arrangements and on time charters.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “will,” “may,” “should,” “expect,” “targets,” “likely,” “would,” “could,” “seeks,” “continue,” “possible,” “might,” “pending” and similar expressions, terms or phrases may identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including, without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs, or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: the strength of world economies, fluctuations in currencies and interest rates, general market conditions, including fluctuations in charter rates and vessel values, changes in demand in the tanker shipping industry, changes in the supply of vessels, changes in worldwide oil production and consumption and storage, changes in our operating expenses, including bunker prices, crew costs, drydocking and insurance costs, our future operating or financial results, availability of financing and refinancing including with respect to vessels we agree to acquire, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, the length and severity of epidemics and pandemics, including COVID-19, and their impact on the demand for seaborne transportation of petroleum and other types of products, general domestic and international political conditions or events, including “trade wars”, armed conflicts including the war in Ukraine and the war between Israel and Hamas, the imposition of new international sanctions, acts by terrorists or acts of piracy on ocean-going vessels, potential disruption of shipping routes due to accidents, labor disputes or political events, vessel breakdowns and instances of off-hires and other important factors. Please see our filings with the US Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.



Corporate Contact:
Andreas Michalopoulos
Chief Executive Officer, Director and Secretary
Telephone: +30-216-600-2400
Email: [email protected]
Website: www.pshipping.com

Investor and Media Relations:
Edward Nebb
Comm-Counsellors, LLC
Telephone: +1-203-972-8350
Email: [email protected]